Anna Dąbrowska‐Iwanicka

832 total citations
26 papers, 442 citations indexed

About

Anna Dąbrowska‐Iwanicka is a scholar working on Pathology and Forensic Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Anna Dąbrowska‐Iwanicka has authored 26 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 9 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Anna Dąbrowska‐Iwanicka's work include Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Anna Dąbrowska‐Iwanicka is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Anna Dąbrowska‐Iwanicka collaborates with scholars based in Poland, United States and Spain. Anna Dąbrowska‐Iwanicka's co-authors include Marek Jakóbisiak, Jakub Gołąb, Maria Marczak, Wojciech Feleszko, Adam Giermasz, Jan Walewski, Anna Czajka, Tomasz Stokłosa, Magdalena Winiarska and Dominika Nowis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Anna Dąbrowska‐Iwanicka

24 papers receiving 433 citations

Peers

Countries citing papers authored by Anna Dąbrowska‐Iwanicka

Since Specialization

Citations

This map shows the geographic impact of Anna Dąbrowska‐Iwanicka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Dąbrowska‐Iwanicka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Dąbrowska‐Iwanicka more than expected).

Fields of papers citing papers by Anna Dąbrowska‐Iwanicka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Dąbrowska‐Iwanicka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Dąbrowska‐Iwanicka. The network helps show where Anna Dąbrowska‐Iwanicka may publish in the future.

Co-authorship network of co-authors of Anna Dąbrowska‐Iwanicka

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Dąbrowska‐Iwanicka. A scholar is included among the top collaborators of Anna Dąbrowska‐Iwanicka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Dąbrowska‐Iwanicka. Anna Dąbrowska‐Iwanicka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor 2024 ·Blood ·Grzegorz S. Nowakowski, Anna Dąbrowska‐Iwanicka, Christian Grommes, Han W. Tun, (unknown), (unknown), (unknown), Radhakrishnan Ramchandren, Andrés J.M. Ferreri, Gaurav S. Choudhary, (unknown), Dora Ferrari, (unknown), (unknown), (unknown), (unknown)	2
2	Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL). 2024 ·Journal of Clinical Oncology ·(unknown), Han W. Tun, (unknown), Anna Dąbrowska‐Iwanicka, Lucía Regales, (unknown), Dora Ferrari, (unknown), (unknown), (unknown), (unknown), (unknown), Christopher R. D’Angelo, Grzegorz S. Nowakowski	2
3	POS1415 ENDOTHELIAL INFLAMMAGING AND MITOCHONDRIAL DYSFUNCTION IN THE ANTIPHOSPHOLIPID SYNDROME 2023 ·Annals of the Rheumatic Diseases ·Charis Pericleous, (unknown), (unknown), Anna Dąbrowska‐Iwanicka, Koralia Paschalaki, David Carling, Andrea Randi, Deepa J. Arachchillage, Justin C. Mason	1
4	DLBCL: who is high risk and how should treatment be optimized? 2023 ·Blood ·Anna Dąbrowska‐Iwanicka, Grzegorz S. Nowakowski	15
5	High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up 2022 ·Scientific Reports ·Joanna Romejko‐Jarosińska, (unknown), Anna Dąbrowska‐Iwanicka, Katarzyna Domańska‐Czyż, Grzegorz Rymkiewicz, Ewa Paszkiewicz‐Kozik, (unknown), (unknown), Agnieszka Druzd‐Sitek, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jan Walewski	6
6	Leczenie wenetoklaksem młodego pacjenta z przewlekłą białaczką limfocytową z delecją 17p i nawrotem choroby po pierwszej linii leczenia — opis przypadku i przegląd literatury 2021 ·Anna Dąbrowska‐Iwanicka, (unknown), Renata Woroniecka, Grzegorz Rymkiewicz, Jan Walewski	1
7	Subcutaneous Compared to Intravenous Administration of Rituximab Plus CHOP in Patients with Diffuse Large B-Cell Lymphoma — a Study By the Polish Lymphoma Research Group 2017 ·Blood ·Ewa Paszkiewicz‐Kozik, Monika Długosz‐Danecka, Paweł Robak, (unknown), (unknown), (unknown), Joanna Romejko‐Jarosińska, Katarzyna Domańska‐Czyż, Marcin Szymański, Marta Morawska, (unknown), (unknown), (unknown), Anna Dąbrowska‐Iwanicka, Jan Walewski	2
8	Primary Mediastinal Large B-cell Lymphoma 2014 ·Current Hematologic Malignancy Reports ·Anna Dąbrowska‐Iwanicka, Jan Walewski	28
9	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib 2010 ·American Journal Of Pathology ·Dominika Nowis, Michał Mączewski, Urszula Mackiewicz, Marek Kujawa, Anna Ratajska, Mariusz R. Wiȩckowski, Grzegorz M. Wilczyński, Monika Malinowska, Jacek Bil, (unknown), Marek Bugajski, Cezary Wójcik, Maciej Siński, Piotr Abramczyk, Magdalena Winiarska, Anna Dąbrowska‐Iwanicka, Jerzy Duszyński, Marek Jakóbisiak, Jakub Gołąb	101
10	Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience 2010 ·Annals of Hematology ·Grzegorz Basak, Wanda Knopińska‐Posłuszny, Magdalena Matuszak, (unknown), (unknown), Anna Szmigielska‐Kapłon, Donata Urbaniak‐Kujda, Jarosław Dybko, (unknown), Anna Dąbrowska‐Iwanicka, (unknown), Piotr Rzepecki, (unknown), W Wiktor-Jędrzejczak	29
11	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity 2010 ·Blood ·Jacek Bil, Magdalena Winiarska, Dominika Nowis, Kamil Bojarczuk, Anna Dąbrowska‐Iwanicka, Grzegorz Basak, K Sułek, Marek Jakóbisiak, Jakub Gołąb	39
12	Primary mediastinal B-cell lymphoma treated with intensive chemotherapy and rituximab compared to CHOP—15 year experience from a single institution 2008 ·Journal of Clinical Oncology ·Anna Dąbrowska‐Iwanicka, (unknown), (unknown), (unknown), (unknown), Nicola Goekbuget, D. Hoelzer, Jan Walewski	1
13	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice 2002 ·Oncology Reports ·Adam Giermasz, Marcin Makowski, Dominika Nowis, Ahmad Jalili, Małgorzata Maj, Anna Dąbrowska‐Iwanicka, Anna Czajka, Marek Jakóbisiak, Jakub Gołąb	5
14	Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice 2002 ·Journal of Cancer Research and Clinical Oncology ·Anna Dąbrowska‐Iwanicka, (unknown), Ahmad Jalili, Marcin Makowski, Tomasz Grzela, Maria Marczak, Grażyna Hoser, Adam Giermasz, Jakub Gołąb, Marek Jakóbisiak	6
15	Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. 2001 ·PubMed ·Anna Dąbrowska‐Iwanicka, Adam Giermasz, Jakub Gołąb, Marek Jakóbisiak	5
16	Lovastatin and tumor necrosis factor-? exhibit potentiated antitumor effects against Ha-ras-transformed murine tumorVia inhibition of tumor-induced angiogenesis 1999 ·International Journal of Cancer ·Wojciech Feleszko, (unknown), (unknown), Maria Marczak, Anna Dąbrowska‐Iwanicka, Adam Giermasz, Anna Czajka, (unknown)	84
17	Lovastatin and tumor necrosis factor‐α exhibit potentiated antitumor effects against Ha‐ras‐transformed murine tumor Via inhibition of tumor‐induced angiogenesis 1999 ·International Journal of Cancer ·Wojciech Feleszko, (unknown), (unknown), Maria Marczak, Anna Dąbrowska‐Iwanicka, Adam Giermasz, Anna Czajka, Marek Jakóbisiak	1
18	Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. 1998 ·PubMed ·Radosław Zagożdżon, Tomasz Stokłosa, Jakub Gołąb, Adam Giermasz, Anna Dąbrowska‐Iwanicka, Witold Lasek, Marek Jakóbisiak	18
19	Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice. 1998 ·PubMed ·Jakub Gołąb, Radosław Zagożdżon, Tomasz Stokłosa, (unknown), Anna Dąbrowska‐Iwanicka, Adam Giermasz, Wojciech Feleszko, Marek Jakóbisiak	5
20	Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice 1997 ·Cancer Immunology Immunotherapy ·Witold Lasek, Wojciech Feleszko, Jakub Gołąb, Tomasz Stokłosa, Maria Marczak, Anna Dąbrowska‐Iwanicka, Magdalena Malejczyk, Marek Jakóbisiak	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact